Brief: AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer

Thermo Fisher Scientific

02/03/2026 14:01

March 2 (Reuters) - AIM ImmunoTech Inc AIM.A:

AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCER

AIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGEN

Source text: ID:nGNXzn7Pq

Further company coverage: AIM.A

 ((Reuters.Briefs@thomsonreuters.com;))